Hemovent

The company's core product is the MOBYBOX system, a compact and portable ECLS device. Weighing less than 2kg, it is designed to fit in a backpack, enabling its use in mobile scenarios like patient transport and field rescues, in addition to intensive care units. A key feature of the MOBYBOX is that it operates pneumatically, driven by oxygen or compressed air, and does not require software or an external power supply. This integrated system manages both blood perfusion and gas exchange in a single device. The product received its CE mark under the Medical Device Directive (MDD) in 2019 and later achieved the more stringent EU Medical Device Regulation (MDR) certification.

Hemovent's business model centers on the development and sale of this ECLS technology to hospitals and critical care providers. Before its acquisition, the company had successfully raised $16.7 million over three funding rounds, with its Series A in 2016 raising $6 million and a Series B extension in 2020 adding $5.5 million, backed by investors like MIG Capital, KfW, and NRW.BANK. The acquisition by MicroPort is intended to leverage MicroPort's global reach to expand the distribution of the MOBYBOX system, including pursuing FDA filing in the US and clinical registration in China.